Safety Validated for 3 Parenteral Iron Formulations, But Cost of Treatment Varies

Web Exclusives - Conference Correspondent

ORLANDO—Three parenteral iron formulations were found to be very safe, with no anaphylactic reactions observed, in a single-center study presented at the 2010 American Society of Hematology Annual Meeting & Exposition.

The study was presented by Maureen Okam, MD, MPH, and Elyse Mandell, MSN, RNCS, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston.

Anemia is a common problem in hematology practice. Oral iron is the first-line treatment, although parenteral iron often is used as well. Before the 1990s, the only US Food and Drug Administration–approved intravenous (IV) product was iron dextran, which was associated, though rarely, with fatal anaphylactic reactions. Since then, 3 new and “safer” iron formulations were approved: iron sucrose, sodium ferric gluconate, and most recently ferumoxytol.

“Randomized clinical trials examining the effectiveness of oral iron repletion compared to IV iron have yielded contradictory results, nevertheless there are clear indications for parenteral iron use,” said Okam. ”It remains unclear which of the available iron formulations used in the US is safest.”

The study therefore compared, by chart review, the adverse reaction rates of 3 formulations of parenteral iron used by 510 patients between 2008 and 2010 at Dana-Farber. Investigators documented that 59% of patients received ferric gluconate, 23% received iron dextran, and 18% received iron sucrose. The comparison did not include the newest drug, ferumoxytol, which is not used at her center.

The overall adverse reaction rate was just 2.8%, Okam reported. By product, adverse events were observed in 2.3% of patients given ferric gluconate, 1.7% given iron dextran, and 5.4% given iron sucrose. The specific reactions are shown in the Table.

“Based on our single-center experience, we found IV iron to be safe, and determined that iron dextran was just as safe as the other products,” she said.

On one hand the average wholesale price of the products is comparable, but fewer visits are required for treatment with iron dextran (1 dose) and iron sucrose (3 doses), compared with ferric gluconate (8 doses). The total cost of treatment, therefore, is less with these 2 agents, she added.

“On the other hand, ferric gluconate was particularly well tolerated in our study,” she pointed out.

Too few events occurred to show a difference in reaction severity, although a larger study might elucidate potential differences, she said.

Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS 2018
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: February 20, 2019